McKesson Corporation (MCK) exhibits 3.6% gross margins and 38.6% return on invested capital within Health Care (Other Pharmaceuticals), balanced against a 19.5x enterprise multiple and 6.7% implied options volatility.
Sustained 3.6% gross profitability converts into 1.5% operating margin and 38.6% ROIC, outpacing sector cost of capital.
ROIC: 38.6% // GM: 3.6%YoY revenue trajectory of +12.4% paired with 5.00% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +12.4% // FCF YLD: 5.00%Altman Z-Score of 6.96 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 6.96 // F-SCORE: 7/9Trading at 24.0x trailing P/E (20.2x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 19.5xOptions market prices a ±6.7% implied move with a 0.76 put/call ratio around $961.00 max pain.
IMPL MOVE: ±6.7% // P/C: 0.76Elevated industry capital intensity and customer concentration in Other Pharmaceuticals require continuous execution to defend 1.2% net margins.
NET MARGIN: 1.2% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MCK & activate live FRED threshold breach alerts.